Everspin's MRAM story already looks priced in on expectations. It needs a clearer catalyst showing visibility into space-computing infrastructure before the shares can move higher. x.com 

Everspin's execution does not match its monopoly: revenue growth has been inconsistent and margins all over the place, so results look worse than its positioning warrants. It is the world's only at-scale maker of Toggle MRAM, radiation-immune memory the US military uses in missiles, submarines and aerospace. Its new $40M Department of War contract requires it to hand over its process technology if it ever stops making MRAM, and a Microchip partnership adds domestic production in Oregon. x.com 

Everspin Technologies is a high-risk MRAM pure play that could multiply if MRAM scales. Microchip's onshore MRAM foundry deal secures a second source, and expanded production feeds directly into revenue, with defense, space and AI-edge memory demand as beneficiaries. The real test is 2027-2029, when mass production, customer growth and revenue must show up; today expectations exceed results. Risks include a small, volatile company, customer concentration, an early market and production delays. … Show more

Everspin now looks somewhat overvalued, because its monopoly in discrete MRAM does not justify current valuations. x.com 

Everspin is among the weak small caps that would be hit hardest if multiples compress for AI infrastructure suppliers, and it does not deserve a $600M valuation. x.com 

Everspin's MRAM is becoming indispensable for persistent, low-power, high-reliability computing at the edge, in vehicles and in defense, setting up a SanDisk-like breakout on a smaller scale if adoption accelerates. A move to $100 would not be shocking. This is high-conviction speculation: competition from embedded MRAM at scale, density and cost challenges, and a valuation already pricing in optimism make execution risk real, and analyst targets of about $12-18.50 lag the price. x.com  x.com 

Everspin's 38.6% surge to $18.28 after its Q1 beat has likely pulled forward much of the near-term upside: at about $425M, or 7x trailing sales, it already prices in much of 2026-2027 growth. Product sales grew 28% to $14.1M and a $40M defense contract bridges about $16M a year, but reaching $25-$30 needs quarterly revenue above $20M, hinging on July 2026 STT-MRAM qualification and a Microchip ramp with recurring orders not due until 2H 2027. Litigation costs weigh on GAAP income. x.com 

Microchip's long-term foundry deal with Everspin adds quality option value and strengthens its standing as a US specialty manufacturer, though the stock still hinges on inventory, utilization, margins and debt. Microchip will make Everspin's MRAM and TMR sensor wafers at its Oregon Fab 4 for at least ten years, putting idle capacity to work as an ITAR-ready onshore source. First shipments target late 2027 and volumes are small, so the near-term earnings impact is limited. x.com  x.com  x.com  x.com  … Show more

Everspin is the only US-domiciled, US-manufactured MRAM maker, and its non-volatile, fast, radiation-hardened memory works where flash and DRAM cannot, making it a Pentagon supplier with no alternative. Its 10-year Microchip deal for a copy-exact line in Oregon doubles domestic capacity from H2 2027. Its UNISYST NOR flash replacement targets 5-10% of a $3 billion market, with production in 2027. It had 238 design wins in 2025, up 34%, with 52.7% gross margins and no debt. x.com  x.com  x.com  x.com  … Show more

CoreWeave and Nebius could get hit as the SpaceX IPO pushes the idea of sending Nvidia GPUs to space, the story needed to justify a $1.5 trillion valuation, with high solar efficiency and no liquid cooling. That could hit terrestrial AI data-center names the way Adobe, Monday.com and Atlassian were hit by Anthropic news. Nebius has a good chart at an all-time high but could face headwinds, and CoreWeave's $65 billion value needs about $12 billion of EBITDA given its heavy capex. x.com